ATE439376T1 - Gag-bindende proteine - Google Patents

Gag-bindende proteine

Info

Publication number
ATE439376T1
ATE439376T1 AT06117339T AT06117339T ATE439376T1 AT E439376 T1 ATE439376 T1 AT E439376T1 AT 06117339 T AT06117339 T AT 06117339T AT 06117339 T AT06117339 T AT 06117339T AT E439376 T1 ATE439376 T1 AT E439376T1
Authority
AT
Austria
Prior art keywords
gag
binding proteins
proteins
binding
Prior art date
Application number
AT06117339T
Other languages
English (en)
Inventor
Andreas J Kungl
Original Assignee
Protaffin Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protaffin Biotechnologie Ag filed Critical Protaffin Biotechnologie Ag
Application granted granted Critical
Publication of ATE439376T1 publication Critical patent/ATE439376T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06117339T 2003-12-04 2004-12-02 Gag-bindende proteine ATE439376T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0195203A AT412785B (de) 2003-12-04 2003-12-04 Gag-bindungsproteine

Publications (1)

Publication Number Publication Date
ATE439376T1 true ATE439376T1 (de) 2009-08-15

Family

ID=33494536

Family Applications (3)

Application Number Title Priority Date Filing Date
AT0195203A AT412785B (de) 2003-12-04 2003-12-04 Gag-bindungsproteine
AT04801190T ATE515269T1 (de) 2003-12-04 2004-12-02 Gag-bindende proteine
AT06117339T ATE439376T1 (de) 2003-12-04 2004-12-02 Gag-bindende proteine

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT0195203A AT412785B (de) 2003-12-04 2003-12-04 Gag-bindungsproteine
AT04801190T ATE515269T1 (de) 2003-12-04 2004-12-02 Gag-bindende proteine

Country Status (20)

Country Link
US (4) US7585937B2 (de)
EP (5) EP2363411A1 (de)
JP (3) JP4980721B2 (de)
KR (2) KR101188785B1 (de)
CN (1) CN1890264B (de)
AT (3) AT412785B (de)
AU (1) AU2004295104B2 (de)
BR (1) BRPI0416544A (de)
CA (1) CA2546789A1 (de)
CY (2) CY1109480T1 (de)
DE (1) DE602004022595D1 (de)
DK (2) DK1689775T3 (de)
ES (2) ES2330362T3 (de)
IL (1) IL175565A0 (de)
NZ (1) NZ547612A (de)
PL (2) PL1752470T3 (de)
PT (2) PT1689775E (de)
SG (1) SG149000A1 (de)
SI (2) SI1689775T1 (de)
WO (1) WO2005054285A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
EP1937815B1 (de) 2005-09-13 2015-05-13 National Research Council of Canada Verfahren und zusammensetzungen zur modulation der tumorzellaktivität
CN100366637C (zh) * 2005-11-17 2008-02-06 中国人民解放军第四军医大学 人白细胞介素8拮抗蛋白及其制备方法
US9422356B2 (en) * 2006-01-31 2016-08-23 Republic Of Korea (Republic Of National Fisheries Research And Development Institute) Artificial signal peptide for expressing an insoluble protein as a soluble active form
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
EP1894571A1 (de) * 2006-08-29 2008-03-05 Protaffin Biotechnologie AG Verwendung von modifizierten IL-8 Proteinen zur Behandlung von Reperfusionsschäden und Transplantatabstossung
US20100075918A1 (en) * 2006-12-08 2010-03-25 Lokeshwar Vinata B Hyaluronidase inhibitors as anti-cancer agents
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
CN101848731A (zh) * 2007-05-07 2010-09-29 肽免疫公司 用作抗体配体的表位定向扩增的方法
EP2042516A1 (de) * 2007-09-27 2009-04-01 Protaffin Biotechnologie AG Glycosaminoglycan-antagonisierende MCP-1-Mutanten und Verfahren zu seiner Verwendung
WO2009054873A2 (en) * 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
EP2053060A1 (de) 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-basierte Glycosamingolycan-Antagonisten und Verfahren zu ihrer Verwendung
WO2009099631A1 (en) 2008-02-08 2009-08-13 Miles Lindsey A Novel plasminogen receptor, polypeptides & antibodies thereof
US20120046218A1 (en) * 2009-01-30 2012-02-23 Protaffin Biotechnologie Ag Glycosaminoglycan-antagonising mcp-i mutants and methods of using same
AU2010294225A1 (en) 2009-09-11 2012-04-05 Protaffin Biotechnologie Ag Composition for treatment of CXCL8-mediated lung inflammation
PT2504363T (pt) 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
EP2686344A1 (de) 2011-03-16 2014-01-22 Protaffin Biotechnologie AG Fgfr1-basierte antagonisten mit verbesserter glycosaminoglycanaffinität und verwendungsverfahren dafür
WO2013007704A2 (en) 2011-07-08 2013-01-17 Protaffin Biotechnologie Ag Novel sdf-1-based glycosaminoglycan antagonist and methods of using same
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
WO2014079957A1 (de) * 2012-11-23 2014-05-30 Bayer Cropscience Ag Selektive inhibition der ethylensignaltransduktion
KR101457371B1 (ko) * 2013-01-10 2014-11-04 강원대학교산학협력단 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물
EP3096776B1 (de) 2014-01-22 2020-12-02 Antagonis Biotherapeutics GmbH Neuartige glycosaminoglycan-antagonisierende fusionsproteine und verfahren zur verwendung davon
EP4021927A1 (de) 2019-08-29 2022-07-06 Antagonis Biotherapeutics GmbH T-zellen mobilisierende cxcl10-mutante mit erhöhter glykosaminoglycan-bindungsaffinität
CN110791523B (zh) * 2019-12-13 2022-05-10 南京农业大学 一种棉花抗旱相关基因GhRCHY1及其应用
KR20250040765A (ko) * 2023-09-15 2025-03-25 (주)케어젠 펩타이드를 유효성분으로 하는 발모 촉진 또는 탈모증의 억제, 예방 또는 개선용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960691A (en) * 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
AU8947791A (en) * 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
ES2125356T3 (es) * 1993-01-08 1999-03-01 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 8.
JP2694321B2 (ja) * 1993-03-10 1997-12-24 大塚製薬株式会社 インターロイキン−１阻害剤
US5527546A (en) * 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
US5866402A (en) 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−８産生阻害剤
US6852696B2 (en) * 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
EP1581615B1 (de) * 2000-09-05 2010-04-28 Biosight Ltd Peptid-konjugierte antikrebs-prodrugs
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
JP2003063980A (ja) * 2001-08-28 2003-03-05 Noevir Co Ltd Ｒａｎｔｅｓ産生阻害剤
US6982170B1 (en) * 2001-12-17 2006-01-03 Maine Medical Center Research Institute Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
JP2003306438A (ja) * 2002-02-18 2003-10-28 Shiseido Co Ltd ケモカイン発現阻害剤
JP2003267887A (ja) * 2002-03-15 2003-09-25 Shiseido Co Ltd ケモカイン発現抑制皮膚外用剤
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EA200401342A1 (ru) * 2002-04-10 2005-08-25 Апплайд Резеч Системз Арс Холдинг Н. В. Новые антагонисты белков mcp
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine

Also Published As

Publication number Publication date
EP2363411A1 (de) 2011-09-07
AT412785B (de) 2005-07-25
AU2004295104A1 (en) 2005-06-16
PT1752470E (pt) 2009-10-15
JP4980721B2 (ja) 2012-07-18
EP2270038A2 (de) 2011-01-05
JP2012139226A (ja) 2012-07-26
EP1689775B1 (de) 2011-07-06
JP2007536906A (ja) 2007-12-20
EP1752470B1 (de) 2009-08-12
US7807413B2 (en) 2010-10-05
US20110144305A1 (en) 2011-06-16
ATA19522003A (de) 2004-12-15
DE602004022595D1 (de) 2009-09-24
US7585937B2 (en) 2009-09-08
US20090005541A1 (en) 2009-01-01
ATE515269T1 (de) 2011-07-15
CN1890264A (zh) 2007-01-03
JP2012165747A (ja) 2012-09-06
KR20070001917A (ko) 2007-01-04
AU2004295104B2 (en) 2010-07-22
KR101278459B1 (ko) 2013-07-01
PL1752470T3 (pl) 2010-01-29
ES2369139T3 (es) 2011-11-25
IL175565A0 (en) 2006-09-05
EP2270038A3 (de) 2011-02-23
US20100331237A1 (en) 2010-12-30
US20080112926A1 (en) 2008-05-15
CY1112330T1 (el) 2015-12-09
CY1109480T1 (el) 2014-08-13
EP1752470A1 (de) 2007-02-14
ES2330362T3 (es) 2009-12-09
DK1689775T3 (da) 2011-09-26
KR20120063542A (ko) 2012-06-15
BRPI0416544A (pt) 2007-01-09
SI1689775T1 (sl) 2011-11-30
CN1890264B (zh) 2014-01-22
CA2546789A1 (en) 2005-06-16
PL1689775T3 (pl) 2011-12-30
PT1689775E (pt) 2011-10-13
EP1689775A1 (de) 2006-08-16
EP2311866A1 (de) 2011-04-20
SG149000A1 (en) 2009-01-29
KR101188785B1 (ko) 2012-10-16
SI1752470T1 (sl) 2009-12-31
DK1752470T3 (da) 2009-12-14
WO2005054285A1 (en) 2005-06-16
NZ547612A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
ATE515269T1 (de) Gag-bindende proteine
NO2017058I1 (no) HPV 58 L1 protein
NO2017012I1 (no) HPV 45 L1 protein
DE602004018654D1 (de) Se
ATE363383T1 (de) Schlingenware
DE502004001683D1 (de) Kabelführung
EP1612464A4 (de) Thermostat
AT502792A5 (de) Düsenanpressvorrichtung
DE502004000672D1 (de) Pigmentpreparationen
DE112004000620D2 (de) Struktoguss
DE10355350A8 (de) Elektromodul
DE502004001524D1 (de) Hydrolager
ATA662003A (de) Trink-mundstück
EP1512745A4 (de) Pigmentprotein
DE502004003122D1 (de) Hydrolager
DE502004005162D1 (de) Leistungsregelvorricthung
DE502004006563D1 (de) Brieftaubenkonstatiersystem
DE10394329D2 (de) Mäanderstent
DE10329218B4 (de) Hotflue
ATE406350T1 (de) Prolinylarylacetamide
DE502004007251D1 (de) En 2-arylpropenalen
DE502004002771D1 (de) Umlenkhebel
DE502004004175D1 (de) Verbrennungskraftmaschime
DE112004001561D2 (de) Getriebene-Antreibseinheit
DE502004002619D1 (de) Flaschenverschluss

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1752470

Country of ref document: EP